Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
131
resultados
Última actualización
04/10/2026 [07:14:00]
Resultados 125 a 131 de 131
Resumen de: CN122351302A
The invention discloses a bifidobacterium microsphere for relieving salmonella typhimurium infection and a preparation method and application thereof, belongs to the technical field of microbial shell-core gel, and particularly relates to a bifidobacterium microsphere for relieving salmonella typhimurium infection. Then dropwise adding into a calcium chloride aqueous solution for first cross-linking, and then immersing into a tannic acid aqueous solution for second cross-linking, thereby obtaining the product. The thermal copolymerization product is obtained by isovolumetric mixing of a polysaccharide aqueous solution and a protein aqueous solution. The invention provides a bifidobacterium microsphere for relieving salmonella typhimurium infection as well as a preparation method and application of the bifidobacterium microsphere, the bifidobacterium microsphere prepared by the invention realizes concentrated responsive release of bifidobacterium at a blind colon part, and the intestinal retention and adhesion colonization efficiency is improved; the relieving effect on salmonella typhimurium infection is better than that of free bacteria, and better intestinal barrier injury repairing and flora adjusting effects are achieved.
Resumen de: WO2026148245A1
The present disclosure relates to microbials for use in E. coli, Salmonella, Enterococcus and/or Clostridium inhibition in animals and their environment. More particularly, the present disclosure relates to isolated Bacillus strains MDG-844 (NRRL No. B-68469), MDG-UF7 (NRRL No. B-68470), MDG-UC25 (NRRL No. B-68471), and MDG-I60 (NRRL No. B-68472), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.
Resumen de: US20260191946A1
This invention relates to the field of biomedicine and specifically to a porcine interferon-like recombinant protein and its applications. By constructing and screening a PoIFN-α DNA shuffling bacterial library, a highly active recombinant protein Porferon was obtained. Porferon exhibits potent anti-infective activity against a broad range of porcine pathogens, including viruses, bacteria, and parasites. Its biological activity is significantly superior to that of natural porcine interferon. As such, Porferon can be used in the development of therapeutics for the prevention or treatment of infectious diseases in pigs, offering a novel and effective solution for clinical applications in veterinary medicine.
Resumen de: CN122342768A
The invention discloses an attenuated salmonella and amodiaquine combined medicine and application. The attenuated salmonella and amodiaquine combined medicine comprises attenuated salmonella typhimurium VNP20009, a derivative of the attenuated salmonella typhimurium VNP20009 or a genetically modified strain of the attenuated salmonella typhimurium VNP20009 and amodiaquine as active components. Almodiaquine is combined with glutathione reductase in neutrophils in a targeting manner and inhibits the activity of the glutathione reductase, so that the neutrophils in a tumor microenvironment are selectively removed. The amodiaquine directly targets glutathione reductase in neutrophile granulocytes, inhibits the activity of the glutathione reductase, reduces the level of reduced glutathione, increases the accumulation of active oxygen, selectively induces the apoptosis of the neutrophile granulocytes in a tumor immune microenvironment, and further enhances the colonization of VNP20009 and derivatives or gene modified strains thereof in tumors. According to the combined therapy, the tumor weight is reduced by about 50%, the tumor growth multiplication time is prolonged by 1.5 times, the neutrophil level of peripheral blood and important organs is not influenced, and the liver and kidney toxicity of VNP20009 and derivatives or gene modified strains thereof is remarkably reduced.
Resumen de: CN122344544A
The invention belongs to the field of gene engineering and medical engineering, and discloses application of virK gene in regulation and control of virulence of klebsiella pneumoniae. Through transcriptome analysis, the expression level of the virK gene in a polymyxin drug-resistant mutant strain is obviously improved. Further research shows that the expression of the gene is regulated and controlled by a PhoP/PhoQ two-component regulation and control system. The virK gene deletion mutant strain and the complementary strain thereof are constructed, and the virulence difference of the virK gene deletion mutant strain and the complementary strain is compared in an animal infection model, so that the virulence of the virK deletion strain is obviously reduced, and the virulence phenotype of the complementary strain can be recovered, which indicates that the virK gene plays an important role in regulation and control of the virulence of klebsiella pneumoniae. It is found for the first time that PhoP can regulate and control virK gene expression, and the virulence phenotype of klebsiella pneumoniae is affected through the regulation and control way, so that a new virulence regulation and control mechanism is disclosed, and a theoretical basis is provided for subsequent targeted intervention.
Nº publicación: CN122344247A 07/07/2026
Solicitante:
UNIV TIANJIN SCIENCE & TECH
\u5929\u6D25\u79D1\u6280\u5927\u5B66
Resumen de: CN122344247A
The invention belongs to the technical field of medicine, and discloses a mannose-modified nano-silver cluster, a preparation method and application of the mannose-modified nano-silver cluster as a probe, the mannose-modified nano-silver cluster is obtained by coupling bovine serum albumin-nano-silver cluster and modified mannose through an acid amine condensation reaction, 14 modified mannose molecules are coupled to each bovine serum albumin molecule, the mannose modified nano-silver cluster can be used as a probe to be applied to biological recognition and targeted marking, and a novel visual tool is provided for receptor-ligand interaction research and drug delivery monitoring. The application development of the carbohydrate probe in biomedical detection and diagnosis and treatment is promoted.
BOPI
Sede Electrónica
